Targets › FCER1A
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 3; Immunology; next expected readout Jun 2027.
High-affinity receptor for immunoglobulin epsilon/IgE. Mediates IgE effector functions in myeloid cells. Upon IgE binding and antigen/allergen cross-linking initiates signaling pathways that lead to myeloid cell activation and differentiation. (UniProt, P12319)
Open in Phaseline: the race on FCER1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Texas Medical Branch, Galveston | Cromolyn sodium (topical 4%) Mast cell stabilizer | FCER1A | Phase 3 | Burn Scar | Dec 2027 |
| Yuhan | Lesigercept High-affinity IgE receptor (FcεRI) antagonist | FCER1A | Phase 2 | Allergic Diseases | Jun 2027 |
Allergic Diseases (1) Burn Scar (1)
antibody (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.